Cart
sales@molnova.com
Levofloxacin N-oxide
CAS No. 117678-38-3
Levofloxacin N-oxide( —— )
Catalog No. M28153 CAS No. 117678-38-3
Levofloxacin N-oxide is an impurity isolated from levofloxacin.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 111 | Get Quote |
|
| 10MG | 194 | Get Quote |
|
| 25MG | 326 | Get Quote |
|
| 50MG | 491 | Get Quote |
|
| 100MG | 708 | Get Quote |
|
| 500MG | 1467 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameLevofloxacin N-oxide
-
NoteResearch use only, not for human use.
-
Brief DescriptionLevofloxacin N-oxide is an impurity isolated from levofloxacin.
-
DescriptionLevofloxacin N-oxide is an impurity isolated from levofloxacin.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor5-HT4
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number117678-38-3
-
Formula Weight377.4
-
Molecular FormulaC18H20FN3O5
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESFC1=C(N2CCN(CC2)(C)=O)C(OC[C@H](C)N3C=C(C(O)=O)C4=O)=C3C4=C1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Tadayoshi Mikami, et al. 5-Amino-6-chloro-N-[(1-isobutylpiperidin-4-yl)methyl]-2-methylimidazo[1,2-alpha]pyridine-8-carboxamide (CJ-033,466), a novel and selective 5-hydroxytryptamine4 receptor partial agonist: pharmacological profile in vitro and gastroprokinetic effect in conscious dogs. J Pharmacol Exp Ther. 2008 Apr;325(1):190-9.
molnova catalog
related products
-
DHBP
DHBP is an WalKR TCS activator. It works via targeting walk and selectively promoting the lysostaphin-induced lysis activity of the Newman wild-type strain.
-
GRGDSPC
GRGDSPC, a 7-amino acid peptide, is a thiolated cell adhesion peptide.This peptide is an ideal novel targeted non-viral gene delivery vector, which was easy to be synthesized, high efficient and low cytotoxicity.
-
DTP3
DTP3 is a selective MKK7/GADD45β inhibitor, which inhibits cancer-selective NF-κB survival pathway.
